14 results about "Measles" patented technology

The invention belongs to but not limited to the technical field of human and animal health diagnostics, and discloses a binding molecule for acute infection diagnosis adapted to a point-of-care (POC) scene, an acute infection diagnosis system and a kit. The binding molecule is an antibody, a nano antibody or an aptamer (preferably not combined with IgM) which is specifically combined with a J chain of dIgA, steric hindrance and conformation rearrangement are avoided by combining the J chain, and the flexibility of a compound is kept so as to efficiently combine with an antigen; the diagnostic system and the kit are adapted to POC scenarios (such as lateral flow test strips). The problems that POC deployment is difficult, RAT sensitivity is low and dIgA detection efficiency of CSC is low in existing NAT are solved, and the kit has the advantages of being low in cost, high in specificity and good in stability, can be used for rapid diagnosis of multiple acute infections such as measles and syphilis, fills up related technical gaps and has high commercial value.

The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3) ), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.

The invention provides a method for rescuing a novel measles recombinant coronavirus. The pGEM3Zf (+)-T7RNAP plasmid constructed by the invention can be subjected to in-vitro reverse transcription processing to obtain T7RNA polymerase mRNA (messenger Ribonucleic Acid). The method comprises the following steps: by taking an MRC-5 cell as a cell matrix, co-transfecting the MRC-5 cell by using a pT7-MVEZ-COV2S.B.1.617.2 plasmid constructed by the invention and a helper plasmid in a physical electric shock manner, and simultaneously transfecting T7RNA polymerase mRNA (messenger ribonucleic acid). T7RNA polymerase mRNA translates and expresses T7RNA polymerase in an MRC-5 cell, the T7RNA polymerase further drives a T7 promoter, transcription of a full-length plasmid containing all genetic information of the virus and expression of N, P and L genes are started, virus packaging and proliferation are completed in a host cell, and the paramyxovirus with infection activity is obtained.

The present invention relates to recombinant measles viruses expressing Lassa virus polypeptides, in particular immunogenic LASV particles expressed by measles viruses and / or virus-like particles (VLPs) containing Lassa virus proteins. These particles are recombinant infectious particles capable of replicating in a host after administration. The present invention provides means for generating these recombinant infectious particles, in particular nucleic acid constructs, vectors, cells and rescue systems. The present invention also relates to the use of these recombinant infectious particles, in particular in the form of a composition, more specifically in a vaccine formulation, for the treatment or prevention of Lassa virus infection.

The invention provides a capturing probe group and a kit for a measles virus full-length genome and a sequencing method of the measles virus full-length genome, and belongs to the technical field of virus detection. The invention relates to an inactive probe group of a measles virus full-length genome. The inactive probe group comprises probes with nucleotide sequences as shown in SEQ ID NO: 1-SEQ ID NO: 742. The capturing probe group and next-generation sequencing are combined to obtain a measles full-length genome sequence. Compared with a primer or a probe used in a sequencing method in the prior art, the single probe in the probe group is short and high in specificity, the same site is designed by using the imbricate probe, all variations of the site are covered, and when a virus sequence is captured, the probe group has the characteristics of high sensitivity, high coverage rate and high flux.

The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3) ), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.

The disclosure provides live attenuated measles vectors encoding in their genome one or more heterologous genes encoding Epstein-Barr Virus (EBV) proteins, e.g., gp350, gH, gL, and gp42, and variants thereof, as well as nucleic acid constructs encoding such measles vectors. The disclosure also relates to immunogenic compositions comprising live attenuated measles vectors encoding EBV proteins, immunogenic compositions comprising such measles vectors, and use of such measles vectors and immunogenic compositions to induce an immune response to EBV in subjects.

The disclosure provides live attenuated measles vectors encoding in their genome one or more heterologous genes for herpes simplex virus (HSV) proteins, e.g., glycoprotein B, glycoprotein C, glycoprotein D, and variants thereof, as well as nucleic acid constructs encoding such measles vectors. The disclosure also relates to immunogenic compositions comprising live attenuated measles vectors encoding HSV proteins, immunogenic compositions comprising such measles vectors, and use of such measles vectors and immunogenic compositions to induce an immune response to HSV in subjects.

The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3)), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.

Embodiments of immunogens comprising a recombinant Mumps (MuV) F ectodomain trimer stabilized in a prefusion conformation or a recombinant Measles (MeV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also provided are embodiments of immunogens comprising chimeric proteins comprising the recombinant MuV or MeV F ectodomain trimer and one or more MuV HN or MeV H ectodomains. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits MuV and / or MeV infection in a subject.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and discloses a traditional Chinese medicine composition, a traditional Chinese medicine preparation and a preparation method and application thereof. According to the preparation method, the traditional Chinese medicine composition and the preparation thereof provided by the invention, the extraction transfer rate of active effective components of the prescription medicines is improved; the traditional Chinese medicine composition can be used for reducing body temperature, resisting viruses, and / or treating cold and cough, upper respiratory tract infection, acute and chronic tracheal and bronchitis, pneumonia, bronchial asthma, measles combined pneumonia, children pertussis and / or pungent and cool catharsis, clearing lung and relieving asthma, and relieving cough and reducing phlegm.

The utility model relates to the technical field of paper diapers, and provides a pair of flexible lining bubble waistline pull-ups which is good in sweat absorption effect and capable of preventing measles caused by sweating and comprises a pant body and extending openings formed in the two sides of the pant body, and the pant body comprises a wrapping layer and a water absorption layer arranged on the inner surface of the middle position of the wrapping layer. A sweat-absorbing buffer layer is arranged on the upper portion of the inner surface of the wrapping layer, and after the wrapping layer is attached to the body, the sweat-absorbing buffer layer is used for conducting pressure buffering on the part where the body is fixed and absorbing sweat generated by the body at the same time.

1. The name of the design product: medicine packaging bag (Xiao'er Majiang granules). 2. The use of the design product: the medicine packaging bag is used for packaging (Xiao'er Majiang granules). 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: front view. 5. The design product is a thin product, so the left view is omitted; the design product is a thin product, so the right view is omitted; the design product is a thin product, so the top view is omitted; the design product is a thin product, so the bottom view is omitted.

The invention relates to the technical field of massage cushions, in particular to an improved moxibustion massage cushion which comprises a cushion main machine and a moxibustion assembly, the cushion main machine comprises a shell, an electrothermal film, a control panel and a power supply device, and the moxibustion assembly comprises a breathable bottom layer, a breathable surface layer and a medicament layer arranged between the breathable bottom layer and the breathable surface layer. A heating table corresponding to the moxibustion assembly in position is arranged on the top face of the shell, and the electric heating film is located under the heating table and abuts against the inner wall of the shell. The moxibustion assembly is flatly laid on the heating table, the heating table is used for heating the moxibustion assembly, and when a user sits on the breathable surface layer, the medicine layer is heated to conduct moxibustion physical therapy on the buttocks of the user. Due to the design of the soft breathable bottom layer and the soft breathable surface layer, the problem that the buttocks have measles due to the fact that the moxibustion assembly is airtight is effectively avoided, the moxibustion assembly can be independently detached after being used and is convenient to clean and replace, in addition, the moxibustion effect of the moxibustion material is fully exerted, and practicability is high.